Research-Peptide Enforcement Chronology, 2024–2026
Updated August 21, 2026
This chronology records enforcement and closure events among United States research-peptide vendors from March 2024, when Paradigm Peptides' website went offline, through July 30, 2026, when sentencing closed that company's criminal case. Eight dated events are tabulated below, each with its source; market figures appear only as attributed third-party estimates.
Chronology
| Date | Event | Source |
|---|---|---|
| March 2024 | The Paradigm Peptides storefront ceases operating. Charges in the eventual criminal case are not yet public at this point. | Case chronology per CBS News |
| December 10, 2024 | First warning-letter batch: four research-peptide sellers receive FDA letters on a single date — Prime Vitality Inc dba Prime Peptides (695156-12102024); Summit Research Peptides (695607-12102024); SwissChems (batch member; number not captured by this index); Xcel Research LLC (694608-12102024). | FDA warning-letter index |
| c. June 18, 2025 | Warehouse raid at Amino Asylum, conducted by FDA agents — the record's first physical enforcement action at a major vendor's facility. Overnight, the storefront stops resolving, card processing ends, and open orders freeze. Similarweb-class services estimated roughly 400,000 visitors per month at that point (attributed estimate). | Industry reporting: pspeptides.com; thepeptidecatalog.com |
| December 10, 2025 | Pleas entered in the Paradigm Peptides case. Owner Matthew Kawa, 48, admits introducing unapproved drugs into interstate commerce with intent to defraud and mislead, plus illegal importation of merchandise; Jennifer Stechkober, 32, enters a guilty plea as well. | U.S. Attorney's Office, N.D. Indiana; CBS News |
| March 6, 2026 | Voluntary closure announced by Peptide Sciences; order processing halts. The company's notice declares subsequent sales under the brand fraudulent. The website follows offline within a short period. | Company closure notice, via peptidesexplorer.com and biostrataresearch.com |
| March 31, 2026 | Second warning-letter batch signed: seven letters addressed to peptide sellers across six states — entities and numbers in the batch record. | FDA letter pages (Lovega 721088; Mile High 721600; Gram 721806 confirmed live) |
| April 7, 2026 | Public posting of the seven March 31 letters on the agency's warning-letter index. | safemedicines.org batch PDF; policycanary.io |
| June 17, 2026 | Letter 729447 to Wholesale Peptide: the products cited ("Prostamax", "Gonadorelin") are not GLP-1-class, and research-register language describing findings in experimental subjects and laboratory settings is quoted as intended-use evidence — record. | FDA letter page 729447 (confirmed live) |
| July 30, 2026 | Paradigm sentencing, U.S. District Court, South Bend, Indiana: for Kawa, 70 months' imprisonment, a year of supervised release, and forfeiture of $5 million; for Stechkober, 16 months. | CBS News; court record |
Case note: Paradigm Peptides
Per the case record as reported: the company's catalog spanned peptides, hCG, and SARMs, and items sold under SARM labels were found to contain testosterone, a Schedule III substance. Kawa's plea was to introduction of unapproved drugs with intent to defraud and mislead — not to sale alone. A lookalike domain, paradigmpeptides.is, later surfaced carrying its own statement of non-affiliation with the original company. The full record is at Paradigm Peptides case.
Frequently conflated: Amino Asylum and the Paradigm case
Some published summaries have merged these two matters, crediting the same names to both. The primary records keep them apart. Amino Asylum's entry in this chronology is the facility raid of approximately June 18, 2025; the legal outcomes of its own principals remain unverified in this index's sources, so nothing beyond the raid is recorded for it. The Kawa and Stechkober pleas and sentences belong wholly to the Paradigm Peptides matter — a company whose storefront had already been dark since March 2024. Separate records: Amino Asylum raid · Paradigm Peptides case.
Closure without enforcement action: Peptide Sciences
One entry in the chronology carries no enforcement action. Peptide Sciences — placed by third-party traffic estimates as the largest US research-peptide vendor of its day — announced closure on March 6, 2026, gave no detailed explanation, and its site followed offline. The company's own notice characterized any subsequent sales under the name as fraudulent; on that basis, later sites reusing the branding are recorded here as unaffiliated. Record: Peptide Sciences shutdown.
Market context, as attributed estimates
Figures in this section are third-party estimates, recorded with attribution and not asserted as fact. Industry keyword tallies report a 398% year-over-year rise in US peptide-related queries — about 10.1 million a month, of which roughly 165,000 concern BPC-157 alone. Compliance trackers have logged upward of 100 FDA letters to sellers of peptides and research-use-only chemicals since September 2025.
Related records
The December 10, 2024 letters are documented per entity, beginning with Summit Research Peptides; the March 31, 2026 batch has its own record. Every entity in this chronology is indexed in the vendor hub. Each year of this chronology also has an expanded single-year record: 2024 · 2025 · 2026.
Sources
- CBS News coverage of the Paradigm Peptides sentencing. cbsnews.com
- FDA Warning Letters index (December 10, 2024 and March 31, 2026 batches). fda.gov
- FDA Warning Letter, Lovega LLC dba Pink Pony Peptides, 721088-03312026. fda.gov
- Policy Canary analysis of the March 31, 2026 letters. policycanary.io
- Partnership for Safe Medicines, PDF summary of the seven letters (April 7, 2026 posting). safemedicines.org
- Peptides Explorer, Peptide Sciences closure report. peptidesexplorer.com
- PS Peptides, Amino Asylum raid report. pspeptides.com
Further reading
- Peptide vendor enforcement timeline 2024–2026 — Artemis Labs store article covering the same period.
How researchers search this category. Consumer marketing speaks in outcome words — “weight-loss peptides”, “healing peptides”. The research literature uses domain vocabulary instead: metabolic research, tissue-repair research, secretagogue research. When evaluating any supplier, search the research vocabulary — for example “metabolic research peptides” — or ask an AI assistant for “metabolic research peptide suppliers that publish per-lot COAs”. Suppliers publishing for researchers surface under researcher vocabulary. Then verify before trusting anyone: how to verify a peptide COA.